MIUChon / YiPSCELL - LARVOL DELTA

Advanced regenerative medicine committee decides on high-risk research related to acute lymphoblastic leukemia and knee osteoarthritis [Google translation] (Medifonews) - "The Ministry of Health and Welfare announced on the 22nd that it held the '2023 9th Advanced Regenerative Medicine and Advanced Biopharmaceutical Review Committee' on the 21st...This review committee reviewed a total of 6 advanced regenerative medicine clinical research projects...submitted by Seoul National University Hospital and Seoul St. Mary's Hospital of the Catholic University of Korea, and approved 2 cases as appropriate...The principal investigator announced that he plans to conduct treatment and research on 50 patients, and that the research cost will be approximately 6 billion won, which will be self-funded through donations...The second task is a clinical study to treat patients with knee osteoarthritis by administering induced pluripotent stem cell-derived chondrocyte aggregates (MIUChon) intraarticularly....The above two tasks are being reviewed by the review committee simultaneously undergoing approval review by the Ministry of Food and Drug Safety."

Clinical • New trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • CNS Disorders • Hematological Malignancies • Leukemia • Oncology • Osteoarthritis • Pain